NCT06484816View on ClinicalTrials.gov

TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 8, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

June 30, 2027

Conditions
Non Small Cell Lung CancerAdvanced Solid TumorHematologic Malignancy
Interventions
DRUG

TGRX-1942

At dose escalation phase, TGRX-1942 will be given orally to patient once a day under a 7-dose sequence of 4mg, 10mg, 20mg, 30mg, 40mg, 50mg, and 60mg. The dose level a particular patient will be assigned depends on the progression of the study and PI evaluation on the safety of previous dose group(s).

Trial Locations (1)

310009

RECRUITING

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

Sir Run Run Shaw Hospital

OTHER

lead

Shenzhen TargetRx, Inc.

INDUSTRY